L Scarfo\textsuperscript{1,2,3}, S Zibellini\textsuperscript{4}, A Tedeschi\textsuperscript{4}, F Maura\textsuperscript{4}, A Neri\textsuperscript{4}, P Bertazzoni\textsuperscript{1}, B Sarina\textsuperscript{4}, G Nalli\textsuperscript{4}, M Motta\textsuperscript{4,10}, FRossini\textsuperscript{1,11}, A Cortezzii\textsuperscript{4}, M Montillo\textsuperscript{5}, E Orlandi\textsuperscript{4} and P Ghia\textsuperscript{1,2,12,13}
on behalf of Rete Ematologica Lombarda (REL) - CLL workgroup
\textsuperscript{1}Laboratory of B cell Neoplasia, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milano, Italy;
\textsuperscript{2}Lymphoma Unit, Department of Onco-Hematology, Istituto Scientifico San Raffaele, Milano, Italy;
\textsuperscript{3}Institute of Hematology, Università degli Studi di Ferrara, Ferrara, Italy;
\textsuperscript{4}Department of Onco-Hematology, Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;
\textsuperscript{5}Department of Oncology/Hematology, Division of Hematology, Niguarda Ca’ Granda Hospital, Milano, Italy;
\textsuperscript{6}Enatomo 1-CTMO, Dipartimento di Scienze Mediche Università di Milano, Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico, Milano, Italy;
\textsuperscript{7}Division of Hematologic Oncology, Istituto Europeo di Oncologia, Milano, Italy;
\textsuperscript{8}Department of Onco-Hematology, Istituto Clinico Humanitas, Milano, Italy;
\textsuperscript{9}Department of Internal Medicine, Presidio Ospedaliero di Lodi, Lodi, Italy;
\textsuperscript{10}Division of Hematology, Spedali Civili, Brescia, Italy;
\textsuperscript{11}Divisione di Ematologia e Centro TMO, Ospedale San Gerardo, Monza, Italy;
\textsuperscript{12}Università Vita-Salute San Raffaele and Istituto Raffaele Ricerca San Raffaele, Milano, Italy and
\textsuperscript{13}MAGIC (Microenvironment and Genes in Cancers of the blood) Interdivisional Research Program, Istituto Scientifico San Raffaele, Milano, Italy
E-mail: marco.montillo@OspedaleNiguarda.it

REFERENCES
1 Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia? Haematologica 2001; 86: 8 - 12.
2 Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005; 130: 325 - 332.
3 Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 2010; 24: 512 - 520.
4 Hallek M,Chesson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446 - 5456.
5 Scarfo L, Dagklis A, Sciuzio C, Fazi C, Ghia P. CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? Semin Cancer Biol 2010; 20: 384 - 390.
6 Dagklis A, Fazi C, Sala C, Cantarelli V, Sciuzio C, Massacane R et al. The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. Blood 2009; 114: 26 - 32.
7 Rawstron AC, Bennett FL, O’Connor SJ, Kwok M, Fenton JA, Plummer M et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359: 575 - 583.
8 Rawstron AC, Shanafelt T, Lanasa MC, Landgren O, Hanson C, Orfao A et al. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom 2010; 78 (Suppl 1): 519 - 523.
9 Shanafelt TD, Kay NE, Jenkins G, Call TG, Zent CS, Jelinek DF et al. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis based on clinical outcome. Blood 2009; 113: 4188 - 4196.
10 Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Maddocks K et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 3959 - 3963.
11 Rossi D, Sozzi E, Puma A, De Paoli L, Rasi S, Spina V et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol 2009; 146: 64 - 75.
12 Molica S, Mauro FR, Giannarelli D, Laura F, Cortezzii A, Brugali et al. Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. Haematologica 2010; 96: 277 - 283.
13 Faguet GB, Agee JF, Marti GE. CDS and cCALL extension in chronic lymphocytic leukaemia (CLL): demonstration of their relative prevalence and that of other common B-CLL markers. Leuk Lymphoma 1992; 6: 335 - 344.
14 Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Schwager SM et al. Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population. Leukemia 2012; 26: 373 - 376.
15 Gibson SE, Swerdlow SH, Ferry JA, Surti U, Dal Cin P, Harris HL et al. Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. Haematologica 2011; 96: 1144 - 1152.

Open
Clonal relationship between langerhans cell histiocytosis and myeloid sarcoma

Leukemia (2012) 26, 1707–1710; doi:10.1038/leu.2012.27

Langerhans cells (LCs) represent the main antigen capturing, processing and presenting dendritic cells (DCs) resident in epithelial surfaces including the skin or the oral mucosa, thus leading to either the induction of immune responses or tolerance. They are classically considered as myeloid-derived DCs sharing initial steps of their differentiation with monocytes. LC histiocytosis (LCH) and the more aggressive variant LC sarcoma (LCS) are considered as the neoplastic counterparts of this DC cell type. The immunoreactivity for macrophage-associated antigens in conjunction with CD1a, S-100 protein and langerin (CD207) represents a useful tool to establish the diagnosis of LCH in paraffin-embedded material.\textsuperscript{1} Rare cases of neoplasms with LC differentiation features developing in patients previously diagnosed with follicular lymphoma or acute lymphoblastic lymphoma/leukaemia (ALL) of T- and B-cell lineage have been reported. In these cases, identical clonal IgH- or TCR\textgamma-gene rearrangements were detected in the H/DC neoplasms and the lymphomas consistent with a common clonal origin.\textsuperscript{2-5} The development of the histiocytic dendritic/cell (H/DC) neoplasm was associated with progressive disease in most of these cases. Thus, it has been suggested that these tumours may represent a part of the clonal evolution of the underlying lymphomas.\textsuperscript{6} The development of a LCS in a patient with an acute B-ALL in complete remission for 9 years has been attributed to a transcription factor-induced transdifferentiation.\textsuperscript{7,8} Both neoplasms showed an identical IgH rearrangement, but different expressions of PAX5 and ID2.\textsuperscript{9}

Only rarely, an association of LCH and acute myeloid leukaemia (AML) has been reported. In most of these cases, the AML developed subsequently to LCH and this was considered as a therapy-related
Here, we describe a concomitant occurrence of LCH and a myeloid sarcoma (MS) characterized by the presence of the same chromosomal aberration (trisomy 8) in both populations.

A 61-year-old woman was seen by her dental surgeon because of an enlarging gingival mass. An excisional biopsy measuring 1.3 cm in diameter was performed at region 26 and...
submitted by the referring pathologist for consultation to the Berlin Reference Centre for Lymphoma and Hematopathology. The patient had been well without a significant past medical history until approximately 3 months earlier when fatigue and anaemia developed. A bone marrow aspirate with 7% myeloblasts and an isolated trisomy 8 were consistent with a refractory anaemia with blast excess-1 (RAEB-1). As her clinical and haematological conditions appeared stable, she was monitored without therapeutic intervention. The formalin-fixed paraffin-embedded biopsy of the oral mucosa (Figure 1a) showed a tumour-forming infiltration by mononuclear cells with heterogeneous morphological and immunophenotypic features. Sheets of medium- to large-sized cells with grooved nuclei and a pale basophilic cytoplasm expressed CD1a, CD11b, CD13, CD14 and CD33 and partially expressed HLA-DR, CD11b, CD13, CD14 and CD33 and partially expressed HLA-DR and showed a trisomy 8 when examined by FISH. The larger-sized cells (asterisks) were negative for myeloperoxidase (Figure 1c), CD34, CD3, CD20 and CD30 but strongly expressed CD1a (Figure 1f), protein S100, langerin (CD207, Figures 1g and h) and Id2 (Figure 1i). Combined immunolabelling (FICTION) with a langerin antibody (Novocastra, Newcastle Upon Tyne, UK) and interphase cytogenetics by FISH with a CEP 8 spectrum green direct-labelled fluorescent DNA probe kit (Abbott Laboratories, Abbott Diagnostics, Abbott Park, IL, USA) was performed. FICTION provided evidence that trisomy 8 and langerin expression were both harboured by identical cells (Figure 1j). In addition, confocal laser-scanning microscopy (CLSM) revealed the presence of myeloperoxidase-positive myeloid blasts (red) among the langerin-positive LCHCs (yellow) in conjunction with CD1a and langerin in a subpopulation of trisomy 8-positive tumour cells. This coexpression represents a phenotypic aberrancy consistent with a differentiation of myeloid blasts towards LCHCs in vivo. DCs can be generated from AML blasts in vitro but do not display typical morphological and immunophenotypic features of LCs.

The clonality of LCH has only rarely been assessed based on the X-chromosomal inactivation mosaicism in somatic tissues and polymorphism of the androgen receptor gene in female patients. To our knowledge, this is the first report demonstrating a focus of LCH within an MS developing in the buccal mucosa where both neoplastic populations displayed the same cytogenetic abnormality, that is, trisomy 8, as the pre-existing myeloid disorder. Interestingly, trisomy 8 has been detected in 10.4% of MS studied before allogeneic haematopoietic stem cell transplantation could be performed. This adverse outcome is in concordance with the data of Pileri et al., suggesting that this aberrancy may be recurrently associated with the development of a MS. Noteworthy, FISH and cytogenetic analyses provided corresponding results in this study, confirming that FISH is a useful tool in cases where only formalin-fixed, but no fresh material is available. Unfortunately, our patient rapidly succumbed to her disease before allogeneic haematopoietic stem cell transplantation could be performed.

The clonality of LCH has only rarely been assessed based on the X-chromosomal inactivation mosaicism in somatic tissues and polymorphism of the androgen receptor gene in female patients. To our knowledge, this is the first report demonstrating a focus of LCH within an MS developing in the buccal mucosa where both neoplastic populations displayed the same cytogenetic abnormality, that is, trisomy 8, as the pre-existing myeloid disorder. Interestingly, trisomy 8 has been detected in 10.4% of MS studied before allogeneic haematopoietic stem cell transplantation could be performed. This adverse outcome is in concordance with the data of Pileri et al., suggesting that this aberrancy may be recurrently associated with the development of a MS. Noteworthy, FISH and cytogenetic analyses provided corresponding results in this study, confirming that FISH is a useful tool in cases where only formalin-fixed, but no fresh material is available. Unfortunately, our patient rapidly succumbed to her disease before allogeneic haematopoietic stem cell transplantation could be performed. This adverse outcome is in concordance with the data of Pileri et al., suggesting that all of their MS patients with positive cytogenetics died of their disease irrespective of their age or the type of their MS. By contrast to the unfavourable prognosis of MS, long-lasting responses have been obtained in adult LCH by multi-drug chemotherapy. Thus, rapid detection of phenotypic heterogeneity of tumour cells in biopsy specimens is mandatory for the choice of the best treatment modality. The factors responsible for the induction of a dichotomous phenotype in the trisomy 8-positive neoplastic cells of our patient are not yet understood. The high Id2 expression levels that we observed in the LCH component of our case suggests that a deregulation of this dominant negative helix-loop-helix transcription factor of the pluripotent and pericardial effusions developed. A buccal swab was suggestive of malignant cells. Despite 5-azacytidine treatment the patient died of progressive disease 4 months after the initial manifestation of MS. No autopsy was performed.

An MS is defined as a mass of myeloid cells occurring in an extramedullary site previously, simultaneously or subsequently to an AML or a myeloproliferative neoplasm. It may be preceded by a MDS, as seen in our patient. In rare cases, an MS may represent the unique manifestation of a myeloid neoplasm without bone marrow involvement at any time of the disease. The evidence of a trisomy 8 in both the components of the oral mass lesion of our patient strongly supports the conclusion that these neoplasms were clonally related. In a large cohort of 92 cases of MS, Pileri et al. could not describe a LCH but identified foci of plasmacytoid monocyte differentiation within an obvious myeloid population in four cases. In two of these cases, both the cellular components showed an opposite phenotype but belonged to the same clone. An inversion 16 was detected in the tumour-forming accumulations of plasmacytoid monocytes and in the myeloid population. This observation was in accordance with the hypothesis that the occurrence of plasmacytoid monocytes in the course of myeloid disorders may represent a differentiation of the underlying disorder. CLSM imaging of our case showed myeloperoxidase in conjunction with CD1a and langerin in a subpopulation of trisomy 8-positive tumour cells. This coexpression represents a phenotypic aberrancy consistent with a differentiation of myeloid blasts towards LCHCs in vivo. DCs can be generated from AML blasts in vitro but do not display typical morphological and immunophenotypic features of LCs.

Letters to the Editor

© 2012 Macmillan Publishers Limited
Leukemia (2012) 1681 - 1729

Figure 1. (a) Histologic aspect of the Giemsa-stained gingival biopsy characterized by a broad-based mass located beneath the oral surface mucosa (m). (b) Large LCHCs with grooved nuclei and pale cytoplasm (asterisks) as well as smaller blasts with oval or delicately folded nuclei and indistinct nucleoli (arrowheads) were observed (Giemsa). The blasts (arrowheads) expressed myeloperoxidase (c) CD33 (d) and showed a finely granular CD68 staining (e). While LCHCs were negative for myeloperoxidase (c, asterisks) they were labelled by CD1a (f), langerin (g, h, confocal image) and Id2 (i) antibodies. By FISH analysis using a DNA probe for trisomy 8 (green) and immunostaining for langerin (red), a trisomy 8 (arrows) was clearly detected in LCHCs (j). CLSM imaging of double stains for myeloperoxidase (red) and langerin (yellow) showed the presence of scattered myeloperoxidase-positive blasts within the sheets of langerin-positive LCHCs (k). There was evidence of a rare coexpressions of both antigens in identical cells, which were stained both in red and in yellow (i, arrows).
CONFLICT OF INTEREST

The authors declare no conflict of interest.

AH Schmitt-Graeff¹, H Duerkop², B Vollmer-Kary¹, S Haxelmanns³, R Nitschke⁴, P Fisch¹, U Germing⁴ and H Stein²

¹Institute of Pathology, University Hospital Freiburg, Freiburg, Germany;
²Berlin Reference Centre for Lymphoma and Hematopathology and Pathodiagnostik, Berlin, Germany;
³Life Imaging Center, Center for Biological Systems Analysis (ZBSA) Albert-Ludwigs-University, Freiburg, Germany and
⁴Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University of Duesseldorf, Duesseldorf, Germany
E-mail: annette.schmitt-graeff@uniklinik-freiburg.de

REFERENCES

1 Jaffe R, Weiss LM, Faccetti F. Tumours derived from Langerhans cells. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds) WHO classification of tumours of the haematopoietic and lymphoid tissues. IARC Press: Lyon, 2008, pp 358–362.
2 Feldman AL, Minniti C, Santi M, Downing JR, Raffeld M, Jaffe ES. Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. Lancet Oncol 2004; 5: 248–250.
3 Feldman AL, Berthold F, Arcenci RJ, Abramovskys C, Shehata BM, Mann KP et al. Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol 2005; 6: 435–437.
4 Feldman AL, Arber DA, Pittaluga S, Martinez A, Burke JS, Raffeld M et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood 2008; 111: 5433–5439.
5 Ratei R, Hummel M, Anagnostopoulous I, Jähne D, Arnold R, Dörken B et al. Common clonal origin of an acute B-lymphoblastic leukaemia and a Langerhans’ cell sarcoma: evidence for hematopoietic plasticity. Haematologica 2010; 95: 1461–1466.
6 Egeler RM, Neglia JP, Arico` M, Favara BE, Heitger A, Nesbit ME. Acute leukemia in association with Langerhans cell histiocytosis. Med Pediatr Oncol 1994; 23: 81–85.
7 Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 2007; 21: 340–350.
8 Gong L, Zhang WD, Li YH, Liu XY, Yao L, Han XJ et al. Clonal status and clinicopathological features of Langerhanscell histiocytosis. J Int Med Res 2010; 38: 1099–1105.

Germline copy number variation associated with Mendelian inheritance of CLL in two families

Leukemia (2012) 26, 1710–1713; doi:10.1038/leu.2012.33

Chronic lymphocytic leukemia (CLL) shows significant familial predisposition, yet few genes have been associated with disease risk. We have used high-resolution single nucleotide polymorphism (SNP) arrays to study familial CLL and lymphoproliferative disorders (LPDs), focusing on a cohort of 44 families that includes 58 individuals with CLL (Supplementary Table 1). Thirty-one of these families met the classic definition of familial CLL, namely at least two first degree relatives with CLL, whereas the remaining thirteen families had a proband with CLL and at least one first degree relative with another LPD. A parallel experiment was undertaken in 103 sporadic CLL patients enrolled on our prospective CLL natural history study and whose data were available for comparison. All subjects on both studies signed written informed consent before participation. Gene expression profiling was also performed on the CLL tumor samples when RNA could be obtained.

The SNP array data from the CLL tumors were analyzed initially using the GISTIC method² (Supplementary Figure 1) and showed 13q deletion in 48% of these familial CLLs, trisomy 12 in 15.5%, 11q deletion in only 3.4% and 17p deletion in 6.9% (Supplementary Table 2 and Supplementary Figure 1). 11q deletion was seen in only 2 of 58 samples (Supplementary Figure 1, Supplementary Table 2), suggestive of a low frequency in familial CLL as we previously reported.³ Otherwise, the pattern of somatic abnormalities was similar in familial and sporadic CLLs (Supplementary Table 2).

Detailed manual review of the 13q deletion region common in CLL revealed that family A in Supplementary Table 1 carries a germline deletion located telomeric to the commonly defined minimal region of deletion around mir-15a and mir-16-1, and centered instead on the DLEU7 gene. The affected family includes a father with CLL (generation 1) and his four children, three of whom also developed CLL (generation 2, Figure 1a). The three unaffected children of individual A-2A were assessed for evidence of monoclonal B cell lymphocytosis (MBL)⁴ with four-color flow cytometry and PCR to detect monoclonal IgH rearrangement (Supplementary Figure 2). These individuals had no evidence of MBL as yet but are young. The germline deletion at 13q in this family extends 525 kb on chromosome 13, from position 49,935,614 to 50,461,103, and includes the DLEU7 and RNASHE2B genes (Figures 1b and c). A germline copy number variant (CNV) was not seen at this location in any other individual studied in this experiment (Figure 1b), in our parallel sporadic experiment, or in 143 other normal DNAs from individuals with solid tumors. This deletion excludes the commonly recognized minimal region of deletion around DLEU2, mir-15a and mir-16-1 (Figures 1b and c), loss of which has been shown in knockout animals to result in a CLL-like disease.⁵ However, recent work has suggested that DLEU7 can function as a tumor suppressor gene in CLL,⁶ and that the minimal region of 13q deletion in CLL may also include DLEU7.⁷ Furthermore, a mouse model carrying conditional deletion of DLEU7, RNASEH2B and the mir-15a/mir-16-1 region in B cells develops CLL preferentially to MBL or NHL.⁸ These data taken together support a role for this genomic region in the pathogenesis of CLL.

We found further support for DLEU7 acting as a tumor suppressor gene in CLL when we examined the affected children in generation 2, A-1A and A-2A, both of whom carry this deletion in their germline saliva samples and show deletion of the other allele in their tumor (Figure 1c). In the tumors, A-1A had a

Accepted article preview online 7 February 2012; advance online publication, 2 March 2012